About Adjuvants

What is an Adjuvant?

An adjuvant is essentially a substance that stimulates the immune response to an antigen without having any antigenic effects itself. The phrase “adjuvant” origins from the Latin word “adjuvare”, which means “help” or “helper”.

Learn more about adjuvants and about Isconova’s contribution in the area

Immunology research

Try the next-generation ISCOMS

The new generation of ISCOM technology has opened up new applications in immunological research by overcoming drawbacks once associated with problematic formulations. Isconova’s next-gen adjuvant is easily handled with any antigen.

Try the state-of-the-art adjuvants in your research

Veterinary applications

A license to care

Isconova’s technology plattform is available for licensing for many veterinary vaccine development segments. Our tailored business collaboration models are designed to fit your specific requirements and circumstances.

Read more and view licencing opportunities

Human applications

New opportunities

With its improved performance safety windows, Isconova’s state-of-the-art adjuvant technology platform opens up new possibilities for human vaccine development.

Explore more

Great expectations—Isconova to receive the 2010 Bona Postulata Prize

Friday, February 12th, 2010

Isconova has been awarded the 2010 Bona Postulata Prize, for being a growing company with a great potential to become even more successful. The Bona Postulata Prize [1] is not intended to be a reward [...]

Read more

Study shows that Isconova´s Matrix-M is an excellent pandemic influenza vaccine candidate

Monday, November 23rd, 2009

Uppsala, Sweden, November 23 2009 – At a time like this, when the global society is under a pandemic influenza threat, the need for a safe, effective and antigen dose-sparing adjuvant becomes critical. Isconova announced [...]

Read more

AbISCO compared to other adjuvants

The AbISCO® adjuvant consistently induces the highest proliferation index and high production levels of antibodies.

Vaccines on the market with Isconova’s adjuvant

  • Canvac CCi® – Bordetella bronchiseptica (2007, Pfizer)
  • Equilis® Prequenza – Equine influenza (2006, Intervet, now part of Schering-Plough)
  • Pestigard® – Bovine BVDV (2003, Pfizer)
  • Equity® – Equine LHRH (2002, Pfizer)
  • Equip® – Equine influenza (1993, Schering-Plough. From Oct. 2008, Pfizer)